Viewing Study NCT05909098



Ignite Creation Date: 2024-05-06 @ 7:08 PM
Last Modification Date: 2024-10-26 @ 3:01 PM
Study NCT ID: NCT05909098
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-06-22
First Post: 2023-06-02

Brief Title: Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for RelapsedRefractory Non-Hodgkins B-cell Lymphoma
Sponsor: Xiangyang No1 Peoples Hospital
Organization: Xiangyang No1 Peoples Hospital

Study Overview

Official Title: Xiangyang No1 Peoples Hospital Hubei University of Medicine
Status: NOT_YET_RECRUITING
Status Verified Date: 2023-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsedrefractory non-Hodgkins B-cell lymphoma The locations isXiangyang No1 Peoples Hospital Hubei University of Medicine The population was relapsedrefractory non-Hodgkins B-cell lymphoma The sample size was 33 The intervention was R-GemOx regimen combined with autologous NK cells The dose of autologous NK cells was body surface area x 2-4 x 109 cells The course of treatment was once every 14 days The primary outcome measure was ORR The duration of assessment was for each treatment cycle 1 month 3 months 6 months 9 months 12 months 18 months 24 months 3 years and 5 years of treatment
Detailed Description: This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsedrefractory non-Hodgkins B-cell lymphoma The locations isXiangyang No1 Peoples Hospital Hubei University of Medicine The population was relapsedrefractory non-Hodgkins B-cell lymphoma The sample size was 33 The intervention was R-GemOx regimen combined with autologous NK cells The dose of autologous NK cells was body surface area x 2-4 x 109 cells The course of treatment was once every 14 days The primary outcome measure was ORR The duration of assessment was for each treatment cycle 1 month 3 months 6 months 9 months 12 months 18 months 24 months 3 years and 5 years of treatment

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None